Top

Journal of Cardiovascular Magnetic Resonance

Published in:

Open Access 01-12-2017 | Research

Ferumoxytol enhanced black-blood cardiovascular magnetic resonance imaging

Authors: Kim-Lien Nguyen, Eun-Ah Park, Takegawa Yoshida, Peng Hu, J. Paul Finn

Published in: Journal of Cardiovascular Magnetic Resonance | Issue 1/2017

Abstract

Background

Bright-blood and black-blood cardiovascular magnetic resonance (CMR) techniques are frequently employed together during a clinical exam because of their complementary features. While valuable, existing black-blood CMR approaches are flow dependent and prone to failure. We aim to assess the effectiveness and reliability of ferumoxytol enhanced (FE) Half-Fourier Single-shot Turbo Spin-echo (HASTE) imaging without magnetization preparation pulses to yield uniform intra-luminal blood signal suppression by comparing FE-HASTE with pre-ferumoxytol HASTE imaging.

Methods

This study was IRB-approved and HIPAA compliant. Consecutive patients who were referred for FE-CMR between June 2013 and February 2017 were enrolled. Qualitative image scores reflecting the degree and reliability of blood signal suppression were based on a 3-point Likert scale, with 3 reflecting perfect suppression. For quantitative evaluation, homogeneity indices (defined as standard deviation of the left atrial signal intensity) and signal-to-noise ratios (SNR) for vascular lumens and cardiac chambers were measured.

Results

Of the 340 unique patients who underwent FE-CMR, HASTE was performed in 257. Ninety-three patients had both pre-ferumoxytol HASTE and FE-HASTE, and were included in this analysis. Qualitative image scores reflecting the degree and reliability of blood signal suppression were significantly higher for FE-HASTE images (2.9 [IQR 2.8–3.0] vs 1.8 [IQR 1.6–2.1], p < 0.001). Inter-reader agreement was moderate (k = 0.50, 95% CI 0.45–0.55). Blood signal suppression was more complete on FE-HASTE images than on pre-ferumoxytol HASTE, as indicated by lower mean homogeneity indices (24.5 [IQR 18.0–32.8] vs 108.0 [IQR 65.0–170.4], p < 0.001) and lower blood pool SNR for all regions (5.6 [IQR 3.2–10.0] vs 21.5 [IQR 12.5–39.4], p < 0.001).

Conclusion

FE-HASTE black-blood imaging offers an effective, reliable, and simple approach for flow independent blood signal suppression. The technique holds promise as a fast and routine complement to bright-blood cardiovascular imaging with ferumoxytol.

Available only for authorised users

Finn JP, Nael K, Deshpande V, Ratib O, Laub G. Cardiac MR imaging: state of the technology. Radiology. 2006;241:338–54.CrossRefPubMed

Bradley WG Jr. Carmen lecture. Flow phenomena in MR imaging. AJR Am J Roentgenol. 1988;150:983–94.CrossRefPubMed

Patel MR, Klufas RA, Alberico RA, Edelman RR. Half-fourier acquisition single-shot turbo spin-echo (HASTE) MR: comparison with fast spin-echo MR in diseases of the brain. AJNR Am J Neuroradiol. 1997;18:1635–40.PubMed

Edelman RR, Chien D, Kim D. Fast selective black blood MR imaging. Radiology. 1991;181:655–60.CrossRefPubMed

Finn JP, Nguyen KL, Han F, Zhou Z, Salusky I, Ayad I, Hu P. Cardiovascular MRI with ferumoxytol. Clin Radiol. 2016;71:796–806.CrossRefPubMed

Bashir MR, Bhatti L, Marin D, Nelson RC. Emerging applications for ferumoxytol as a contrast agent in MRI. J Magn Reson Imaging. 2015;41:884–98.CrossRefPubMed

Bashir MR, Mody R, Neville A, Javan R, Seaman D, Kim CY, Gupta RT, Jaffe TA. Retrospective assessment of the utility of an iron-based agent for contrast-enhanced magnetic resonance venography in patients with endstage renal diseases. J Magn Reson Imaging. 2014;40:113–8.CrossRefPubMed

Winterer JT, Lehnhardt S, Schneider B, Neumann K, Allmann KH, Laubenberger J, Langer M. MRI of heart morphology. Comparison of nongradient echo sequences with single- and multislice acquisition. Investig Radiol. 1999;34:516–22.CrossRef

Nguyen KL, Yoshida T, Han F, Ayad I, Reemtsen BL, Salusky IB, Satou GM, Hu P, Finn JP. MRI with ferumoxytol: a single center experience of safety across the age spectrum. J Magn Reson Imaging. 2017;45(3):804–12. [Epub 2016 Aug 2]CrossRefPubMed

10.

Hennig J, Nauerth A, Friedburg H. RARE imaging: a fast imaging method for clinical MR. Mag Reson Med. 1986;3:823–33.CrossRef

11.

Simonetti OP, Finn JP, White RD, Laub G, Henry DA. “black blood” T2-weighted inversion-recovery MR imaging of the heart. Radiology. 1996;199:49–57.CrossRefPubMed

12.

Edelman RR, Mattle HP, Wallner B, Bajakian R, Kleefield J, Kent C, Skillman JJ, Mendel JB, Atkinson DJ. Extracranial carotid arteries: evaluation with “black blood” MR angiography. Radiology. 1990;177:45–50.CrossRefPubMed

13.

Nguyen TD, de Rochefort L, Spincemaille P, Cham MD, Weinsaft JW, Prince MR, Wang Y. Effective motion-sensitizing magnetization preparation for black blood magnetic resonance imaging of the heart. J Magn Reson Imaging. 2008;28:1092–100.CrossRefPubMedPubMedCentral

14.

Wang J, Yarnykh VL, Hatsukami T, Chu B, Balu N, Yuan C. Improved suppression of plaque-mimicking artifacts in black-blood carotid atherosclerosis imaging using a multislice motion-sensitized driven-equilibrium (MSDE) turbo spin-echo (TSE) sequence. Mag Reson Med. 2007;58:973–81.CrossRef

15.

Srinivasan S, Hu P, Kissinger KV, Goddu B, Goepfert L, Schmidt EJ, Kozerke S, Nezafat R. Free-breathing 3D whole-heart black-blood imaging with motion sensitized driven equilibrium. J Magn Reson Imaging. 2012;36:379–86.CrossRefPubMedPubMedCentral

16.

Edelman RR, Botelho M, Pursnani A, Giri S, Koktzoglou I. Improved dark blood imaging of the heart using radial balanced steady-state free precession. J Cardiovasc Magn Reson. 2016;18:69.CrossRefPubMedPubMedCentral

17.

Neuwelt EA, Hamilton BE, Varallyay CG, Rooney WR, Edelman RD, Jacobs PM, Watnick SG. Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)? Kidney Int. 2009;75:465–74.CrossRefPubMed

18.

Finn JP, Nguyen KL and Hu P. Ferumoxytol vs. Gadolinium agents for contrast-enhanced MRI: Thoughts on evolving indications, risks, and benefits. J Magn Reson Imaging. 2017. doi:10.1002/jmri.25580.

19.

Li W, Salanitri J, Tutton S, Dunkle EE, Schneider JR, Caprini JA, Pierchala LN, Jacobs PM, Edelman RR. Lower extremity deep venous thrombosis: evaluation with ferumoxytol-enhanced MR imaging and dual-contrast mechanism--preliminary experience. Radiology. 2007;242:873–81.CrossRefPubMed

20.

Vu AT, Li W, Tutton S, Pierchala L, Prasad P, Edelman RR. Robust and efficient whole heart black blood cine imaging. Proc Intl Soc Mag Reson Med. 2005;13:1638.

21.

U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA strengthens warnings and changes prescribing instructions to decrease the risk of serious allergic reactions with anemia drug Feraheme (ferumoxytol). http://www.fda.gov/Drugs/DrugSafety/ucm440138.htm. Accessed 30 Mar 2015.

22.

Hetzel D, Strauss W, Bernard K, Li Z, Urboniene A, Allen LF. A phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. Am J Hematol. 2014;89:646–50.CrossRefPubMedPubMedCentral

23.

Vadhan-Raj S, Strauss W, Ford D, Bernard K, Boccia R, Li J, Allen LF. Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron. Am J Hematol. 2014;89:7–12.CrossRefPubMed

24.

Macdougall IC, Strauss WE, McLaughlin J, Li Z, Dellanna F, Hertel J. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin J Am Soc Nephrol. 2014;9:705–12.CrossRefPubMedPubMedCentral

25.

Schiller B, Bhat P, Sharma A. Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period. Clin Ther. 2014;36:70–83.CrossRefPubMed

26.

Auerbach M, Strauss W, Auerbach S, Rineer S, Bahrain H. Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min. Am J Hematol. 2013;88:944–7.CrossRefPubMed

27.

Balakrishnan VS, Rao M, Kausz AT, Brenner L, Brenner L, Pereira BJG, Frigo TB, Lewis JM. Physicochemical properties of ferumoxytol, a new intravenous iron preparation. Eur J Clin Investig. 2009;39:489–96.CrossRef

28.

Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJ. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol. 2009;4:386–93.CrossRefPubMedPubMedCentral

29.

Ning P, Zucker EJ, Wong P, Vasanawala SS. Hemodynamic safety and efficacy of ferumoxytol as an intravenous contrast agents in pediatric patients and young adults. Magn Reson Imaging. 2016;34:152–8.CrossRefPubMed

30.

Muehe AM, Feng D, von Eyben R, Luna-Fineman S, Link MP, Muthig T, Huddleston AE, Neuwelt EA, Daldrup-Link HE. Safety report of Ferumoxytol for magnetic resonance imaging in children and young adults. Investig Radiol. 2016;51:221–7.CrossRef

31.

Varallyay CG, Toth GB, Fu R, Netto JP, Firkins J, Ambady P and Neuwelt EA. What Does the Boxed Warning Tell Us? Safe Practice of Using Ferumoxytol as an MRI Contrast Agent. AJNR Am J Neuroradiol. 2017. doi:10.3174/ajnr.A5188.

32.

Clark SF. Iron deficiency anemia. Nutr Clin Pract. 2008;23:128–41.CrossRefPubMed

33.

Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. Lancet. 2016;387:907–16.CrossRefPubMed

34.

Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol. 2009;122:78–86.CrossRefPubMedPubMedCentral

35.

Bradbury MW. Transport of iron in the blood-brain-cerebrospinal fluid system. J Neurochem. 1997;69:443–54.CrossRefPubMed

Title: Ferumoxytol enhanced black-blood cardiovascular magnetic resonance imaging
Authors: Kim-Lien Nguyen
Eun-Ah Park
Takegawa Yoshida
Peng Hu
J. Paul Finn
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Journal of Cardiovascular Magnetic Resonance / Issue 1/2017
Electronic ISSN: 1532-429X
DOI: https://doi.org/10.1186/s12968-017-0422-y

ACC 2024 Congress

Springer Medicine

Ferumoxytol enhanced black-blood cardiovascular magnetic resonance imaging

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2017

Quantification of myocardial deformation in children by cardiovascular magnetic resonance feature tracking: determination of reference values for left ventricular strain and strain rate

Effect of cellular and extracellular pathology assessed by T1 mapping on regional contractile function in hypertrophic cardiomyopathy

Cardiovascular magnetic resonance in an adult human population: serial observations from the multi-ethnic study of atherosclerosis

Review of Journal of Cardiovascular Magnetic Resonance (JCMR) 2015-2016 and transition of the JCMR office to Boston

Prognostic utility of differential tissue characterization of cardiac neoplasm and thrombus via late gadolinium enhancement cardiovascular magnetic resonance among patients with advanced systemic cancer

Dark-blood late gadolinium enhancement without additional magnetization preparation